India's customs department has strengthened the government's regulatory offensive against billionaire Gautam Adani's business operations by backing the health ministry's legal challenge to nicotine pouch sales at airport duty-free shops. In a formal submission to Mumbai's High Court on June 22, customs officials rejected Adani's argument that international departure areas fall outside domestic regulatory jurisdiction, asserting instead that duty-free status provides only tax advantages and carries no exemption from other legal controls.
The conflict centres on a March health inspection at Adani's Mumbai international airport that declared the sale of nicotine pouches unlawful under Indian law. Adani is contesting this finding in court, but the customs department's intervention represents a significant escalation of official pressure on one of India's most prominent business conglomerates. The company has not yet publicly responded to requests for comment on the customs filing.
Adani's legal strategy rests on the assertion that goods sold in sealed bags to departing passengers within the international departure area exist in a regulatory grey zone, subject only to customs jurisdiction rather than health ministry oversight. The group contends that travellers purchasing these products are not supposed to consume them until they have left Indian territory, implying a distinction between point of sale and actual use. This argument attempts to leverage the technical framework of duty-free commerce to shield retail operations from domestic regulations.
Customs authorities have systematically dismantled this reasoning, describing Adani's interpretation as "untenable". Officials noted that once passengers take possession of duty-free goods, they retain complete discretion over consumption, rendering meaningless any legal fiction that goods remain outside India's regulatory reach. The practical reality of passenger behaviour supersedes contractual intent, customs argued, making the health ministry's enforcement authority applicable regardless of where transactions occur.
Nicotine pouches represent one of the world's fastest-expanding nicotine products, gaining substantial market traction in numerous countries while remaining officially unapproved in India. Philip Morris International, a major manufacturer, has reported dramatic growth in its Zyn brand sales across the United States, with American revenues doubling between 2023 and the following year. This global momentum has likely incentivised retailers to capture Indian market share, even as regulators resist their introduction.
The Adani Group operates eight airports across India and is pursuing an ambitious expansion programme valued at approximately eleven billion US dollars, with duty-free retail operations forming a strategic component of revenue diversification. Since August, the company has imported nicotine pouch brands including Swedish Smokeless Solutions' offerings, with documented imports exceeding 35,000 US dollars in value. This investment in inventory suggests confidence in eventually overcoming regulatory obstacles or belief that market demand justifies legal risk.
For Malaysian observers, the dispute carries broader implications for how South Asian governments are beginning to coordinate regulatory enforcement against multinational consumer goods in ways that transcend traditional commercial frameworks. India's approach—deploying both health and customs authorities simultaneously—signals determination to control nicotine product availability despite corporate political influence. Whether this model might eventually influence Malaysian regulatory stance toward emerging nicotine products remains uncertain, but the precedent of customs authorities reinforcing health ministry positions could reshape regional enforcement architecture.
The case will return to court on July 28, with the next hearing potentially bringing clarity on whether Indian courts will accept the government's position that regulatory jurisdiction attaches to products regardless of their physical location at the moment of sale. Adani's July 13 filing additionally challenged the customs department's authority to issue directives without formal warning notices, introducing procedural questions that might complicate the government's case even if substantive health arguments prove persuasive.
The dispute also illuminates the tension between duty-free commercial operations and modern regulatory frameworks designed to control novel consumption products. As nicotine pouches proliferate globally and manufacturers aggressively pursue emerging markets, retailers and regulators increasingly clash over whether traditional duty-free privileges encompass new product categories that previous generations of legislation never contemplated. India's pushback suggests that regulatory authorities are unwilling to accept legacy commercial arrangements as shields against health policy objectives, a position likely to gain traction across Southeast Asia as these products approach regional markets.
